Submitted by Anonymous (not verified) on 24 August 2026 - 12:16
Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 21, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 21, Status: Authorised